An In-silico Approach to Explore the Possible Multifunctional Neuroprotective Efficacy of Violacein against Ischemic Stroke

Introduction: Cerebral ischemia arise due to insufficient/ interrupted blood supply to brain and is accompanied by pathologies like degradation of extracellular matrix resulting in blood brain barrier disruption, intra cranial haemorrhage, activation of astroglial cells and hence death of neurons. In addition, oxidative stress and inflammation is common to all neurodegenerative diseases enhancing the harmful consequences of diseases.

Matrix Metalloproteinases (MMP) are normally involved in extracellular matrix remodelling and are regulated while injury and inflammation in tissue. Over expression of MMP2 and MMP9 results in progression of ischemic conditions by extracellular matrix degradation thus compromising the structural integrity of Blood Brain Barrier (BBB) proving them a potent targets for the disease.

Violacein (source: Chromobacterium violaceum), purple pigment from microbial origin is a bisindole have high anti-inflammatory, anti-oxidant, anti-bacterial, anti-cancer and anti-parasitic properties. Present study is to study the effective potential of violacein against cerebral ischemia.

Methods and findings: Violacein’s ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity), properties were calculated and structural inhibition of MMPs through molecular docking was evaluated.

Violacein resulted six H-bonds with MMP2 with high binding energy of -11.83 kcal/mol and two H-bonds with MMP9 with binding energy of -9.889 kcal/mol. The Ki values of violacein with MMP2 and MMP9 were 2.12 nM and 56.14 nM respectively which proved high affinity of violacein towards the target.

Conclusion: Violacein with its high antioxidant and anti-inflammatory property can be a potent all round treatment for cerebral ischemia and demands extensive research.


Verma S and Pandey AK

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 16th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
    March 19-21, 2018 Berlin, Germany
  • 4th International Conference on Antibiotics: R&D, B2B April 20-21, 2018 Las Vegas, Nevada, USA
    April 20-21, 2018 Las Vegas, Nevada, USA
  • 1th European Biosimilars Congress April 26-27, 2018 Rome, Italy
    April 26-27, 2018 Rome, Italy
  • 15th Annual European Pharma Congress May 07-09, 2018 Frankfurt, Germany
    May 07-09, 2018 Frankfurt, Germany
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • WorldCat
  • Publons